SRDX - SurModics - Biotech IPO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SRDX - SurModics - Biotech IPO

SRDX 26.95

-1.6%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Will Preska who started this subject	10/29/2003 3:23:45 PM
From: Lance Bredvold	of 84

twobob puts warning into better perspective and speculates on reason for thrombus formation. Usually I try to post the article quoted, but in this case I am copying the whole post from Yahoo to get his opinion and the backup arguments by URL. It will also give me access to the TCT papers and foolish premise listed several of them as good reading earlier this morning--I put them on the side to read before adding them here and got caught up in other activities (a nap). (gg). One of my best resources from TCT I attempted to post here several times a while ago and never could get the URL to come up correctly. So at least this gets one to the site. twobobuk 10/29/03 11:38 am Msg: 6186 of 6252 Thrombosis due to Cypher is not new news and has been well aired on this board if not fully taken on board. eg When the UK issued a warning letter devices.mhra.gov.uk 256D94002EE7FE (edit; while in editing period I attempted to use the above URL. It does get me to a UK site which is probably worthwhile, but perhaps the numbers must be added manually to reach that particular paper. After WhatsNew/FE7A033DA6651DC580 256D98002EE7FE showed on the Yahoo post but not all shows up here). But the big Docs that do JNJ's trials dispute there is a problem tctmd.com Yet the regulators still question which is why we have the FDA releasing a letter today. For myself I have a personal opinion, but no proof, about what the cause may be. The theory is that the rapamycin drug is thinning the fibrous cap of vulnerable plaque causing rupture and thrombus formation. Also people say its only x% thrombus but they miss the big issue of safety versus efficay. The stockmarket is focused on restenosis rates. Is it 8% or 9%? One is better than the other. The regulator focuses on other data - the safety data.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next